Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1542/neo.24-5-e318 | DOI Listing |
J Clin Med
January 2025
"Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Neurofibromatosis is a genetic disorder arising de novo or with an autosomal dominant transmission that typically presents either at birth or in early childhood, manifesting through distinctive clinical features such as multiple café-au-lait spots, benign tumors in the skin, bone enlargement, and deformities. This literature review aims to resume the spectrum of maternal and fetal complications encountered in pregnant women with neurofibromatosis type 1 (NF1). Thorough research was conducted on databases such as Web of Science, PubMed, Science Direct, Google Scholar, and Wiley Online Library.
View Article and Find Full Text PDFAm J Obstet Gynecol
January 2025
Department of Mother and Neonate, Institute for Maternal and Child Health IRCCS Burlo Garofolo, 34137, Trieste, Italy; Department of Medical Surgical and Health Sciences, University of Trieste, 34149, Trieste, Italy.
Background: Identifying fetal growth restriction and distinguishing it from a constitutionally small fetus can be challenging. The umbilical vein blood flow is a surrogate parameter of the amount of oxygen and nutrients delivered to the fetus, providing valuable insights about the function of the placenta. Nevertheless, currently, this parameter is not used in the diagnosis and management of fetal growth restriction.
View Article and Find Full Text PDFAm J Obstet Gynecol
December 2024
Department of Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address:
Background: Early-onset fetal growth restriction as consequence of placental insufficiency frequently requires iatrogenic preterm birth. Administration of antenatal corticosteroids reduces risks of neonatal morbidity and mortality following preterm birth and is most beneficial if the neonate is delivered within 2 weeks following treatment. International guidelines on fetal growth restriction pregnancies do not provide directives regarding the timing of antenatal corticosteroids, resulting in practice variation.
View Article and Find Full Text PDFInt J Gynaecol Obstet
December 2024
Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo, Japan.
Objective: The objective was to study the relationship between a decrease in gross fetal movement during maternal night sleep counted by an objective method and abnormal perinatal outcomes.
Methods: This was a prospective cohort study. A total of 470 pregnant women recorded fetal movement with the fetal movement acceleration measurement recorder weekly after 28 weeks.
Am J Obstet Gynecol
December 2024
Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, UT; Intermountain Healthcare, Maternal-Fetal Medicine, Salt Lake City, UT.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!